Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reference Pricing Clauses In US COVID-19 Contracts Leave Drug Industry Vulnerable

Executive Summary

Innovation and price controls can coexist in the United States, COVID-19 contracts show. But drug pricing experts also acknowledge the unique circumstances of COVID-19 could make such contracts hard to replicate and argue that reference-pricing strategies may have limited ability to lower prices.

You may also be interested in...



Congress Eyes Vaccine Pricing With Spotlight On Pfizer As COVID Boosters Look More Likely

Senate hearing offers early signals that US lawmakers will be closely watching how COVID-19 vaccine pricing evolves. Biden team pledges to try to make contracting more transparent.

Happy Holidays: ‘Most Favored Nation’ Rule Effective Date Likely To Be Delayed

Either through the courts or a postponement by the Trump administration itself, the Medicare Part B rule seems destined to remain dormant instead of going into effect in January as scheduled.

Coronavirus Update: Sanofi And GSK’s Vaccine Suffers Setback

While the new mRNA-based vaccines grow closer to market, Sanofi and GSK's more established approach experiences a serious setback.US authorization in sight for Pfizer/BioNTech after positive advisory committee vote. Pfizer Seeks More Time For EUA Presentation In India.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel